Urology journals recommend new prostate cancer grade groups

2016 ◽  
Vol 13 (7) ◽  
pp. 374-375 ◽  
Author(s):  
Jonathan I. Epstein
Keyword(s):  
2019 ◽  
Author(s):  
Ramy A. Abdelsalam ◽  
Ibrahim Khalifeh ◽  
Alan Box ◽  
Maria Kalantarian ◽  
Sunita Ghosh ◽  
...  

Abstract Background To investigate the incidence and prognostication of ERG, PTEN and SPINK1 protein expressions in prostate cancer cohort of Middle Eastern descent in comparison to published data from Western populationMethods Immunohistochemistry for ERG, PTEN and SPINK1 was performed in cohort of localized PCa (n=340). Data correlated to pathological and clinical outcomes and compared to Western populations.Results ERG expression and PTEN loss noted in 123/288 (42.7%) and 91/297 (30.6%) of patients, respectively. SPINK1 expression assessed in subset of cases, noted in 6/150 (4%) of patients. Only ERG expression was associated with grade groups, being more common in lower grade groups (1-3 vs 4-5; p=0.04). In contrast to Western population, PTEN loss foci were more likely to be ERG negative, observed in 81% of tumor foci and patients with PTEN neg/ERG pos were more likely to exhibit biochemical recurrence (OR 2.831; 95% CI: 1.10-726, p=0.03). This association remained significant in multivariate analysis (OR 2.68; 95% CI: 0.98-7.33, p=0.05), after adjusting for GG, path stage and surgical margin.Conclusion This study documents significant differences in key molecular events in PCa in Middle Eastern population compared to Western populations that could explain differences in PCa incidence, progression and prognostication. ERG, PTEN and SPINK1 genomic alteration occur less frequently and the enrichment of ERG for PTEN loss is not observed. Additionally, patients with combined PTEN loss/ERG positive are at highest rate for BCR vs North American Caucasian population where PTEN loss alone seems to be associated with the worst clinical outcome. The data presented here further support differences in clonal evolution between Middle Eastern and Western population in relation to PCa and add further insight to understanding PCa molecular pathways.


2019 ◽  
Vol 475 (2) ◽  
pp. 223-231 ◽  
Author(s):  
Raquel Albero-González ◽  
Silvia Hernández-Llodrà ◽  
Nuria Juanpere ◽  
Marta Lorenzo ◽  
Adrià Lloret ◽  
...  

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Ariel Schulman ◽  
Lauren Howard ◽  
Kae Jack Tay ◽  
Rajan Gupta ◽  
Efrat Tsivian ◽  
...  

Author(s):  
GYu Kudryavtsev ◽  
LV Kudryavtseva ◽  
LM Mikhaleva ◽  
YaYu Kudryavtseva ◽  
NA Solovyeva ◽  
...  

Prostate cancer is the most common type of cancer among men, which is mainly due to extensive use of screening tests and high total number of prostate biopsies. Verification of tumors with poorer prognosis is the primary goal of prostate cancer management. The study was aimed to determine the clinical and morphological associations and the prognostic value of the Nanog protein expression in prostate cancer of distinct Grade Groups. We used the prostate tissue specimens obtained during surgery, and the biopsy specimens, the total of 89 cases. Histological and immunohistochemical assessment was performed using antibodies to Ki-67 and Nanog. Correlations between the expression of markers and the Grade Groups were revealed using the Spearman's rank correlation coefficient, and the correlation with clinical and morphological characteristics was determined using the chi-squared test (χ2). There was a positive correlation between the expression of Ki-67 and Nanog, and the Grade Group numerical order (rs = 0.619, p < 0.001 and rs = 0.786, p < 0.001 respectively). We managed to find the relationship between the high Nanog expression and the extraprostatic extension (p = 0.041). High expression of Nanog protein in the prostate cancer cells was associated with a higher-grade adenocarcinoma and indicated a poor prognosis.


Cancer ◽  
2017 ◽  
Vol 123 (21) ◽  
pp. 4122-4129 ◽  
Author(s):  
Ariel A. Schulman ◽  
Lauren E. Howard ◽  
Kae Jack Tay ◽  
Efrat Tsivian ◽  
Christina Sze ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Christian Arstad ◽  
Kristin Taskén ◽  
Paulo Refinetti ◽  
Ulrika Axcrona ◽  
Karl-Erik Giercksky ◽  
...  

Primary prostate tumor heterogeneity is poorly understood, leaving research efforts with challenges regarding the initiation and advancement of the disease. The growth of tumor cells is accompanied by mutations in nuclear and in mitochondrial genomes. Thus, mitochondrial DNA mutations may be used as tumor cell markers. By the use of laser capture microdissection coupled with assays for mitochondrial point mutation detection, mtDNA mutations were used to trace mutated cells at a histological level. Point mutations in mtDNA were determined in 12 primary prostate cancers. The tumors represent different pathology-prognostic grade groups. Known mutational hotspots of the mtDNA were scanned for heteroplasmy. All specimens with mtDNA heteroplasmy were subsequently subsampled by laser capture microdissection. From a total number of 1728 microsamples, mitochondrial DNA target sequences were amplified and base substitutions detected by cycling temperature capillary electrophoresis. Real-time PCR was used as a quantitative assay to determine the relative mtDNA copy number of 12 tumors studied, represented by two samples from each (N = 24); a high degree (75%) demonstrated tumor specimen heterogeneity. A grid of 96 spots isolated by laser capture microdissection demonstrated interfocal sample heterogeneity and increased the limit of detection. The spots demonstrated a wide range of mutant fractions from 0 to 100% mutant copies. The mitochondrial DNA copy number in the samples was determined by real-time PCR. No correlation between copy number and pathology-prognostic grade groups was observed. Somatic mitochondrial DNA point mutations represent traceable biomarkers demonstrating heterogeneity in primary prostate cancer. Mutations can be detected in areas before changes in tissue histopathology are evident to the pathologist.


The Prostate ◽  
2017 ◽  
Vol 77 (15) ◽  
pp. 1520-1527 ◽  
Author(s):  
Hideyasu Tsumura ◽  
Hiromichi Ishiyama ◽  
Ken-ichi Tabata ◽  
Hiroki Katsumata ◽  
Momoko Kobayashi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document